Start here if you're new
what it is
Dyne develops drugs for rare muscle diseases.
how it gets paid
Last year Dyne Therapeutics made n/a in revenue. DYNE-101 / DM1 was the main engine at $0, or 25% of sales.
what just happened
Dyne posted a $0.76 loss per share, and the supplied data does not give you revenue.
At a glance
B+ balance sheet — decent shape, but not bulletproof
90/100 earnings predictability — you can trust these numbers
-$3.37 fy2024 eps est
1.4 beta
~$3B market cap
xvary composite: 53/100 — below average
What they do
Dyne develops drugs for rare muscle diseases.
The moat is a platform, not one drug. FORCE is a delivery system that tries to get medicine into muscle and the CNS (central nervous system, the brain and spinal cord). You have 191 employees backing four programs, not a sales machine.
How they make money
n/a
annual revenue
DYNE-101 / DM1
$0
DYNE-251 / DMD
$0
z-rostudirsen / DMD
$0
FSHD and Pompe preclinical
$0
The products that matter
targets myotonic dystrophy type 1
DYNE-101
phase 3 started march 2026
global Phase 3 started in March 2026 after one-year data showed sustained improvement in myotonia and physical function for a disease with no approved therapies.
lead program
targets duchenne muscular dystrophy
z-rostudirsen
5.46% dystrophin
the program restored dystrophin to 5.46% from near-zero and is targeting an FDA filing in the second half of 2026. that moves it from science project to real regulatory event.
filing watch
Key numbers
$115M
long-term debt
Debt is $115M. Against about $3B of market value, that is not the problem.
1.4
beta
A 1.4 beta means the stock tends to swing more than the market. Your nerves need a budget.
5/100
price stability
A 5 score means bigger swings. That is normal for a biotech with no revenue in the data.
90/100
predictability
A 90 score means the loss path is easier to map than most. Trial dates still matter more than models.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $115M (4% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for DYN right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Dyne posted a $0.76 loss per share, and the supplied data does not give you revenue.
This was a pipeline story, not a sales story. The data you gave me shows EPS, but not revenue or gross margin.
-$0.76
eps
n/a
n/a
n/a
n/a
the number that mattered
The $0.76 loss per share mattered because it shows the company is still burning cash while the pipeline does the heavy lifting.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is Phase 3 failure for DYNE-101 in myotonic dystrophy type 1.
med
DYNE-101 fails to hold up in Phase 3
the HARMONIA study only started in March 2026. if the one-year functional benefit seen earlier does not replicate, the lead asset behind a large part of the ~$3B valuation takes a direct hit.
impact: a company with $0 product revenue has no operating business to soften that blow.
med
z-rostudirsen filing slips or gets pushed back
management is targeting an FDA filing in the second half of 2026. if that window moves, the market will immediately reprice both timing and financing risk.
impact: delay matters more when annual operating expenses are already $468M.
med
cash burn forces dilution before approval
Dyne ended with $791.9M in cash and equivalents, which sounds large until you pair it with $468M in annual operating expenses. late-stage biotech cash piles shrink faster than they look.
impact: more capital could come at a lower share price if timelines slip.
med
early biomarker strength does not become durable real-world benefit
5.46% dystrophin restoration is encouraging, and cardiopulmonary signals help, but regulators care about whether biology becomes durable patient benefit. biotech history is full of programs that looked cleaner before the bigger study.
impact: strong mechanistic data alone rarely earns full valuation support.
you own a company with $0 product revenue, $468M in annual operating expenses, and a ~$3B market cap. that leaves very little room for a major clinical disappointment.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the second-half 2026 filing window for z-rostudirsen
this is the nearest named regulatory checkpoint on the page. if the window holds, the story gets more concrete. if it slips, financing risk gets louder.
risk
whether DYNE-101 Phase 3 keeps the earlier functional signal intact
the whole bull case is easier to tell than to prove. Phase 3 is where encouraging rare-disease data has to survive a harsher test.
metric
the expense line versus the cash line
$468M in annual operating expenses against $791.9M in cash is manageable today. it becomes a problem quickly if the clinical calendar drifts.
trend
whether follow-up data keeps strengthening the regulatory story
March 8, 2026 added cardiopulmonary support for z-rostudirsen. the trend matters because rare-disease programs get valued on data durability, not one headline.
Analyst rankings
earnings predictability
90 / 100
in human-speak, the reported numbers usually land where expected. that does not make the science predictable.
beta
1.4
when the market moves, DYN has historically moved about 40% more. not a bunker stock.
risk rank
3
safer than 50% of stocks on this system. read that as balance-sheet support, not clinical certainty.
source: institutional data
Institutional activity
institutional ownership data for DYN is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$16
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive